At what enterprise value was OMEGA PHARMA acquired in 2014?

During the acquisition of OMEGA PHARMA by PERRIGO COMPANY in 2014, the transaction's Enterprise Value is estimated to be in the range of 3b - 100b EUR.

What was the EV/EBITDA of OMEGA PHARMA when it was acquired by PERRIGO COMPANY?

The estimated EV/EBITDA multiple for OMEGA PHARMA is in the range of 10x - 18x.

When was OMEGA PHARMA acquired by PERRIGO COMPANY?

OMEGA PHARMA was acquired by PERRIGO COMPANY in 2014.

What was the revenue of OMEGA PHARMA at the time of the deal?

The revenue of OMEGA PHARMA at the time of the deal is estimated to be in the range of 750M - 1.3b EUR.

What was the EBITDA of OMEGA PHARMA during the acquisition?

OMEGA PHARMA's EBITDA is estimated to be in the range of 250M - 500M EUR.

How is the data for the OMEGA PHARMA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the OMEGA PHARMA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://investor.perrigo.com/2014-11-06-Perrigo-Company-plc-To-Acquire-Omega-Pharma-NV-For-EUR-3-6-Billion-Creating-A-Top-Five-Global-OTC-Company

← DATABASE

Home Database Healthcare & PharmaOMEGA PHARMA

11/2014

OMEGA PHARMA acquired by PERRIGO COMPANY

BELGIUM Life Sciences / Pharma & Biotech / Generics / Labs EV 3b - 100b EUR

Context

Perrigo has completed the acquisition of Omega Pharma. This transaction acts as a massive "commercial accelerator," solving the complex logistical and regulatory barriers inherent in the European pharmacy landscape. By internalizing a sophisticated thirty-five-country distribution network, the group eliminates its dependency on regional third-party agents and secures immediate shelf-space for its expansive US-developed product pipeline. The strategic rationale hinges on the synergy between localized branding expertise and centralized manufacturing scale. While the acquirer provides the industrial backbone and cost-efficiency of a global supplier, the target brings the technical operational depth required to navigate diverse European healthcare systems and consumer preferences.

OMEGA PHARMA, which reported an EBITDA margin of in 2014, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Omega Pharma NV is a Belgian company of over-the-counter (OTC) healthcare solutions. The organization thrives on a philosophy of "pharmacist-focused" growth, prioritizing the development and commercialization of a vast portfolio of non-prescription products. Rather than specializing in a single therapeutic area, the firm utilizes a multi-category approach, maintaining leadership in cough and cold, skincare, pain relief, and weight management. Its value proposition is anchored in its extensive European commercial infrastructure, which facilitates direct relationships with pharmacy networks across dozens of countries. The entity's strategy is fueled by a disciplined brand-building mandate and an agile regulatory framework, ensuring rapid market entry for innovative self-care solutions.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2014

2013

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
07/2015	PERRIGO COMPANY	NATURWOHL PHARMA (YOKEBE)	GERMANY	Generics / Labs
06/2015	BC PARTNERS	PHARMATHEN	GREECE	CDMO
11/2014	QUALIUM	IMV TECHNOLOGIES	FRANCE	R&D Biotech
09/2014	INSTITUT MERIEUX / SAGARD / SOFIPROTEOL	CEVA SANTE ANIMALE	FRANCE	Animal Health
02/2014	MONTAGU PRIVATE EQUITY	NEMERA	FRANCE	Medical Consumables
01/2014	FIVE ARROWS	DUTSCHER	FRANCE	Medical Consumables
10/2013	ARDIAN	LABORATOIRES ANIOS	FRANCE	Medical Consumables
07/2013	CHARTERHOUSE	DOC GENERICI	ITALY	Generics / Labs
06/2013	BC PARTNERS	ANTELLIQ	FRANCE	Animal Health
06/2013	EURAZEO	PÉTERS SURGICAL	FRANCE	Medical Consumables

REFERENCES

Valuation range: EV 3b - 100b EUR

Revenue range: 750M - 1.3b EUR

EBITDA range: 250M - 500M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of OMEGA PHARMA by PERRIGO COMPANY are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.